Products
Haemostatix is developing first-in-class products to treat bleeding in leukaemic patients and in surgery. Bone marrow failure in leukaemic patients, especially when they are undergoing chemotherapy, can result in a severe platelet deficiency, which leads to bleeding. The standard treatment for this is repeated transfusion of donor platelets. However, as a blood-derived product, transfused platelets carry a risk of viral, prion and bacterial contamination. Supply and wastage is also a significant problem as donor platelets have a very short shelf life of 5 days. In addition, the efficacy of platelets may be reduced in up to 20% of patients due to refractory responses. Surveys by Haemostatix confirm the unequivocal need for a synthetic platelet substitute.
More...
In surgery, platelets are also transfused to prevent or control excess bleeding. In this context, platelets have to be ordered ahead of surgery and may not in fact be used, resulting in wastage. Surgery patients are also exposed to contamination risks associated with any platelet transfusion.
There is also a need to control bleeding at the site of an incision or wound. Topical haemostats or sealants have been developed for this application, but their acceptance is limited by concerns over efficacy; the inability to control brisk bleeds; biocompatibility; speed of setting and ease of preparation. Despite these shortcomings, this is a rapidly expanding market, receptive to new product introductions.
More...
| Product |
Description |
Indication |
Status |
| HaemoPlax |
systemic haemostat / iv platelet substitute |
prevention of bleeding in platelet deficient leukaemic patients |
pre-clinical trials |
| HXTC 901 |
systemic haemostat / iv platelet substitute |
control of severe bleeding in leukaemic patients and in surgery |
research |
| HXSA 902 |
topical haemostat / fibrinogen gel |
localised bleeding / wound sealing in surgery and trauma |
research |